IK: A novel cell mitosis regulator that contributes to carcinogenesis

Chao Gao1,2, Yanyan Han3, Lu Bai1,4

  • 1Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.

Insights

The novel cell mitosis regulator IK may play a role in cancer development. Its loss causes cell cycle arrest, and it influences the tumor immune microenvironment by affecting human leukocyte antigen (HLA) class II expression.

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Carcinogenesis involves dysregulated cell growth and death.
  • IK is identified as a novel regulator of cell mitosis.
  • IK's role in cancer and immune response is under investigation.

Purpose of the Study:

  • To review current research on the biological functions and mechanisms of IK in cancer.
  • To explore IK's impact on the tumor immune microenvironment.
  • To discuss the potential clinical significance of IK.

Main Methods:

  • Literature review using PubMed and Web of Science.
  • Analysis of existing studies on IK expression and function.
  • Synthesis of findings regarding IK's role in carcinogenesis and immunity.

Main Results:

  • Loss of IK expression leads to cell mitotic arrest and cell death.
  • IK inhibits interferon gamma (IFN-γ)-induced human leukocyte antigen (HLA) class II antigen expression.
  • IK influences the tumor immune microenvironment.

Conclusions:

  • IK is implicated in cell cycle regulation and may contribute to carcinogenesis.
  • IK modulates immune responses within the tumor microenvironment.
  • Further research into IK's clinical significance is warranted.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.5K